PharmD Mauch - Cencora CEO, President
| COR Stock | USD 227.64 2.18 0.95% |
CEO
PharmD Mauch is CEO, President of Cencora
| Age | 57 |
| Address | 1 West First Avenue, Conshohocken, PA, United States, 19428-1800 |
| Phone | 610 727 7000 |
| Web | https://www.cencora.com |
Cencora Management Efficiency
The company has Return on Asset of 0.031 % which means that on every $100 spent on assets, it made $0.031 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 2.0912 %, implying that it generated $2.0912 on every 100 dollars invested. Cencora's management efficiency ratios could be used to measure how well Cencora manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Cencora's Return On Tangible Assets are relatively stable compared to the past year. As of 12/17/2024, Return On Assets is likely to grow to 0.02, while Return On Capital Employed is likely to drop 0.15. At this time, Cencora's Return On Assets are relatively stable compared to the past year. As of 12/17/2024, Asset Turnover is likely to grow to 5.17, while Intangible Assets are likely to drop slightly above 2.7 B.Similar Executives
| Found 9 records | CEO Age | ||
| Pedro Aguado | Compania Cervecerias Unidas | 50 | |
| Brendan Whitworth | Anheuser Busch Inbev | 45 | |
| Jose Nasrallah | Compania Cervecerias Unidas | 58 | |
| Francisco Dominguez | Compania Cervecerias Unidas | 59 | |
| Carlos Brito | Anheuser Busch Inbev | 60 | |
| CMA FCA | TFI International | 71 | |
| Fernando Sacchi | Compania Cervecerias Unidas | 59 | |
| Domingo Manterola | Compania Cervecerias Unidas | 39 | |
| Michael OLeary | Ryanair Holdings PLC | 63 | |
Management Performance
| Return On Equity | 2.09 | ||||
| Return On Asset | 0.031 |
Cencora Leadership Team
Elected by the shareholders, the Cencora's board of directors comprises two types of representatives: Cencora inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cencora. The board's role is to monitor Cencora's management team and ensure that shareholders' interests are well served. Cencora's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cencora's outside directors are responsible for providing unbiased perspectives on the board's policies.
| PharmD Mauch, CEO, President | ||
| Michael Millegan, Independent Director | ||
| James Cleary, Executive CFO | ||
| Elizabeth JD, Executive Officer | ||
| Bennett Murphy, Senior Relations | ||
| Maile Kaiser, Senior Vice President of Sales | ||
| John Chou, Ex CEO | ||
| Pawan Verma, Chief VP | ||
| Jeffrey Finnin, Chief Financial Officer | ||
| Derek McCandless, Senior Vice President - Legal, General Counsel, Secretary | ||
| David Wilson, Lead Independent Director | ||
| Elizabeth Campbell, Executive Officer | ||
| Silvana Battaglia, Executive Officer | ||
| Leslie Donato, Executive Officer | ||
| Lazarus Krikorian, Chief VP | ||
| Robert Stuckey, Independent Chairman of the Board | ||
| J Quinn, VP Treasurer | ||
| James Attwood, Independent Director | ||
| John Thompson, Independent Director | ||
| Aleksandra Krusko, Senior Vice President Information Technology | ||
| Steven Collis, President Chairman | ||
| Anthony Hatzenbuehler, Senior Vice President Data Center Operations | ||
| Jean Bua, Independent Director | ||
| Michael Koehler, Independent Director | ||
| Paul Szurek, President, Chief Executive Officer, Director | ||
| Ann Anaya, Senior Officer | ||
| Richard Tremonte, EVP Pharmaceuticals | ||
| Gina Clark, Executive Officer | ||
| Juan Font, Senior Vice President - General Management | ||
| Jennifer Dubas, Senior Officer | ||
| Brian Warren, Senior Vice President - Development and Product Engineering | ||
| Kelly Chambliss, Independent Director | ||
| Kathy Gaddes, Ex Officer | ||
| Patricia Higgins, Independent Director | ||
| Steven Smith, Sr. VP of Sales and Marketing | ||
| RPh Nightengale, President Pharmacy |
Cencora Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cencora a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 2.09 | ||||
| Return On Asset | 0.031 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 46.14 B | ||||
| Shares Outstanding | 193.28 M | ||||
| Shares Owned By Insiders | 10.70 % | ||||
| Shares Owned By Institutions | 93.69 % | ||||
| Number Of Shares Shorted | 10.11 M | ||||
| Price To Earning | 82.16 X |
Pair Trading with Cencora
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cencora position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cencora will appreciate offsetting losses from the drop in the long position's value.Moving together with Cencora Stock
Moving against Cencora Stock
The ability to find closely correlated positions to Cencora could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cencora when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cencora - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cencora to buy it.
The correlation of Cencora is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cencora moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cencora moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cencora can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Cencora Stock Analysis
When running Cencora's price analysis, check to measure Cencora's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cencora is operating at the current time. Most of Cencora's value examination focuses on studying past and present price action to predict the probability of Cencora's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cencora's price. Additionally, you may evaluate how the addition of Cencora to your portfolios can decrease your overall portfolio volatility.